ArticleJHEP reports : innovation in hepatology2026
Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: A network meta-analysis.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Glucagon-like peptide-1 receptor agonists and advanced liver outcomes in type 2 diabetes: a systematic review and exploratory meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Incremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- GLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations.Journal of gastroenterology and hepatology · 2026Article
- Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study.Hepatology international · 2026Observational
- GLP-1 receptor agonists at the crossroads of diabetes, hepatic steatosis, and hepatocellular carcinoma.Internal and emergency medicine · 2026Review
- Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes.Frontiers in endocrinology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Glucose-lowering drugs (GLDs) including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been broadly evaluated in patients with coexisting metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). However, their comparative efficacy in reducing the risk of liver-related events remains unclear. Thus, we aim to simultaneously compare the efficacy of different GLDs for patients with MASLD and T2D. Methods: We searched PubMed, EMBASE, Cochrane Library and Web of Science for observational studies from inception to April 2025. We evaluated the comparative efficacy of six GLDs, including GLP-1RAs, SGLT2is, dipeptidyl peptidase-4 inhibitors, metformin, sulfonylureas, and thiazolidinediones using pairwise meta-analysis and Bayesian network meta-analysis. We assessed overall and individual liver-related events, including the development of cirrhosis, decompensation and hepatocellular carcinoma (HCC), with treatments ranked via SUCRA (surface under the cumulative ranking) scores. Results: Twelve studies involving 737,408 patients with MASLD and diabetes were analyzed. Both GLP-1RAs and SGLT2is, when compared to non-GLP-1RA and non-SGLT2i controls, were significantly associated with reduced risk for overall liver-related events (hazard ratio [HR] 0.79, 95% CI 0.70-0.90, and HR 0.75, 95% CI 0.63-0.88, respectively). Similar results were also observed for HCC and liver decompensation (HRs 0.74-0.81). In individuals with obesity, a greater risk reduction was observed for GLP-1RAs (HR 0.74, 95% CI 0.56-0.99) but not for SGLT2is. GLP-1RAs also outperformed SGLT2is in non-Asian populations (HR 0.91, 95% CI 0.83-0.99). Network meta-analysis identified GLP-1RAs and SGLT2is (SUCRA 90%/80%, respectively) as the most effective for risk reduction, with significantly greater efficacy than other GLDs (HRs 0.75-0.79). Conclusions: GLP-1RAs and SGLT2is were associated with reduced risks of liver-related events in patients with MASLD and T2D. GLP-1RAs showed superior benefit in individuals with obesity and in non-Asian populations, supporting a personalized approach to treatment selection. Impact and implications: The long-term liver-related efficacy of different glucose-lowering drugs (GLDs) in patients with coexisting metabolic dysfunction-associated steatotic liver disease and type 2 diabetes remains unclear, despite a higher lifetime risk of advanced liver disease in this population. We evaluated the comparative efficacy of six GLDs by pairwise meta-analysis and Bayesian network meta-analysis, demonstrating GLP-1RAs and SGLT2is may be among the most effective GLDs for reducing liver-related events, with GLP-1RAs appearing particularly beneficial for patients with obesity. These findings support a personalized approach to treatment selection and underscore the need for future clinical trials to confirm the efficacy of GLDs. INPLASY registration number: INPLASY202530085.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.